Trevena Has Been Granted U.S. Patent 11,912,713 Titled "7-membered Aza-Heterocyclic Containing Delta-Opioid Receptor Modulating Compounds, Methods Of Using And Making (For Treating Pain, Migraines, Depression, Parkinsons Disease, And Other Disorders)
Portfolio Pulse from Benzinga Newsdesk
Trevena, Inc. has been granted a U.S. patent (11,912,713) for delta-opioid receptor modulating compounds, aimed at treating pain, migraines, depression, Parkinson's disease, and other disorders. This patent covers the methods of using and making these compounds.
February 27, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trevena, Inc. has secured a significant patent for compounds that modulate delta-opioid receptors, with applications in treating a range of disorders.
The granting of a U.S. patent to Trevena for these compounds is a significant milestone, likely to enhance the company's intellectual property portfolio and potentially lead to new treatments for various disorders. This development could positively impact investor sentiment and the company's valuation in the short term, as it highlights Trevena's innovation capabilities and the potential for future revenue streams from these compounds.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100